Latest Content

Dealing with Insensitivity After Breast Cancer Surgery

June 4th 2025, 5:00pm

By Bonnie Annis

Article

Breast cancer surgery can disfigure the body in some way, and often the scars are more than skin deep, which may worsen by the actions of others.

Nubeqa Combo Positively Impacts HRQoL vs Placebo in Prostate Cancer Subgroup

June 4th 2025, 4:00pm

By Sabrina Serani

Article

Nubeqa and ADT treatment led to positive impacts on health-related quality of life vs placebo in metastatic hormone-sensitive prostate cancer.

Rina-S Yields 50% Response Rate in Advanced Endometrial Cancer

June 4th 2025, 3:00pm

By Spencer Feldman

Article

Rina-S led to a 50% response rate, including two complete responses, in heavily pretreated advanced endometrial cancer, according to early trial findings.

Addressing Unmet Needs for Young Women Before, During and After a Cancer Diagnosis

June 4th 2025, 1:00pm

By Ryan Scott

Article

Natalie Schnaitmann discusses urgent supportive care gaps that affect long-term quality of life for younger women with cancer.

Imdelltra Shows Survival Benefit in Small Cell Lung Cancer

June 3rd 2025, 9:00pm

By Chris Ryan

Article

Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, reinforcing it as a new SOC.

Targeting ESR1 Mutations Early May Improve Outcomes in Breast Cancer

June 3rd 2025, 8:00pm

By Dr. Massimo Cristofanilli

Video

Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.

FDA Approves Nubeqa in Metastatic Castration-Sensitive Prostate Cancer

June 3rd 2025, 7:22pm

By Spencer Feldman

Article

The FDA approved Nubeqa for metastatic castration-sensitive prostate cancer based on significantly improved radiographic progression-free survival data.

You Are Not a Statistic: Facing Cancer With Hope, Not Numbers

June 3rd 2025, 5:00pm

By Linda Cohen

Article

I’m here to prove that powerful phrase; after nearly 16 years living with incurable cancer, I know there’s more to my story than the statistics.

Patritumab Deruxtecan Does Not Improve Survival Outcomes vs Chemo in EGFR+ NSCLC

June 3rd 2025, 4:00pm

By Jason M Broderick

Article

Patritumab deruxtecan treatment did not improve suvival end points versus those treated with chemotherapy in EGFR+ advanced/metastatic NSCLC.

Kisqali Benefit Lasts Across Age in Breast Cancer Subset

June 3rd 2025, 3:00pm

By Gina Mauro

Article

Kisqali plus aromatase inhibitor improved outcomes across age and menopausal status in early hormone receptor–positive, HER2-negative breast cancer.

COCOON Regimen Eases Dermatologic Side Effects After Treatment in EGFR+ NSCLC

June 3rd 2025, 2:00pm

By Russ Conroy

Article

The COCOON dermatologic management regimen reduced the quality-of-life impact of Rybrevant/Lazcluze vs SOC treatment in patients with EGFR-mutated NSCLC.

Akeega Combo Delays Progression in HRR+ Castration-Sensitive Prostate Cancer

June 3rd 2025, 12:00pm

By Silas Inman

Article

Akeega delayed cancer growth and symptoms in patients with castration-sensitive prostate cancer and HRR gene mutations.

Understanding the Side Effects of RLY-2608 in HR+, HER2– Breast Cancer

June 2nd 2025, 9:00pm

By Dr. Sarah Sammons

Video

Dr. Sarah Sammons discusses side effects associated with RLY-2608, and how it effects patients with HR-positive, HER2-negative advanced breast cancer.

Imlunestrant Alone or With Verzenios Improved PROs in Advanced Breast Cancer

June 2nd 2025, 7:00pm

By Tim Cortese

Article

Imlunestrant alone or in combination with Verzenios improved patient-reported outcomes in ER+, HER2– advanced breast cancer following endocrine therapy.

Fotivda Monotherapy Demonstrated Efficacy in Previously Treated Metastatic RCC

June 2nd 2025, 6:00pm

By Dr. Alexander Chehrazi-Raffle

Video

Dr. Alexander Chehrazi-Raffle discusses findings from the phase 3 TiNivo-2 trial, designed to evaluate treatment with Fotivda in patients with metastatic renal cell carcinoma.